Your browser doesn't support javascript.
loading
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.
Pan, Qiuzhong; Weng, Desheng; Liu, Jiayong; Han, Zhaosheng; Ou, Yusheng; Xu, Bushu; Peng, Ruiqing; Que, Yi; Wen, Xizhi; Yang, Jing; Zhong, Shi; Zeng, Lun; Chen, Aiyuan; Gong, Haiping; Lin, Yanmei; Chen, Jiewen; Ma, Ke; Lau, Johnson Y N; Li, Yi; Fan, Zhengfu; Zhang, Xing.
Afiliação
  • Pan Q; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Weng D; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Liu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing 100142, P.R. China.
  • Han Z; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Ou Y; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Xu B; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Peng R; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Que Y; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Wen X; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Yang J; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Zhong S; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Zeng L; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Chen A; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Gong H; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Lin Y; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Chen J; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Ma K; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China.
  • Lau JYN; Axis Therapeutics, Ltd., Hong Kong SAR, P.R. China; Athenex, Conventus Building, 1001 Main Street, Suite 600, Buffalo, NY 14203, USA.
  • Li Y; Xiangxue Life Science Technology (Guangdong) Co., Ltd., Guangzhou 510663, P.R. China. Electronic address: li_yi@gibh.ac.cn.
  • Fan Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing 100142, P.R. China. Electronic address: zhengfufan@126.com.
  • Zhang X; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China. Electronic address: zhangxing@sysucc.org.cn.
Cell Rep Med ; 4(8): 101133, 2023 08 15.
Article em En | MEDLINE | ID: mdl-37586317
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias de Tecidos Moles / Imunoterapia Adotiva Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias de Tecidos Moles / Imunoterapia Adotiva Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2023 Tipo de documento: Article